Completed PHASE1 INTERVENTIONAL 1-arm NCT01222780

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer

Sponsor: Acrotech Biopharma Inc.

Conditions Brain Tumors Leukemia Lymphoma Neuroblastoma Sarcoma Wilms Tumor

Interventions Marqibo

Updated 8 times since 2017 Last updated: Jan 14, 2020 Started: Sep 30, 2010 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Brain Tumors and Leukemia, this trial is completed. The trial is conducted by Acrotech Biopharma Inc. and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2022 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1

Phase: PHASE1_PHASE2 → PHASE1

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acrotech Biopharma Inc.
National Cancer Institute (NCI)

Data source: Acrotech Biopharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States